Skip to main content

Table 3 Risk for significant second primary cancers by age at diagnosis of uterine cancer (left half) and follow-up interval (right half), respectively

From: Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period

SPM site (ICD-9 code)

Agea (years)

O

E

SIR (O/E)

95 % CI

Intervalb (years)

O

E

SIR (O/E)

95 % CI

Small intestine (152)

<50

7

0.27

26.06

(10.44, 53.71)

≤5

6

0.23

25.95

(9.48-56.49)

≥50

5

1.15

4.34

(1.40, 10.14)

≤1

0

0.03

0

NA

     

1-5

6

0.20

29.47

(10.76-64.15)

     

5-10

3

0.38

7.97

(1.60-23.30)

     

≥10

3

0.81

3.69

(0.74-10.79)

Colorectum (153,154)

<50

36

9.68

3.72

(2.60, 5.15)

≤5

58

9.00

6.45

(4.89-8.33)

≥50

83

43.36

1.91

(1.52, 2.37)

≤1

12

1.07

11.25

(5.81-19.66)

     

1-5

46

7.93

5.8

(4.25-7.74)

     

5-10

29

14.05

2.06

(1.38-2.96)

     

≥10

32

30.00

1.07

(0.73-1.51)

Lung (162)

<50

13

6.24

2.08

(1.11, 3.56)

≤5

36

6.22

5.78

(4.05-8.00)

≥50

59

30.57

1.93

(1.47, 2.49)

≤1

7

0.74

9.42

(3.77-19.40)

     

1-5

29

5.48

5.29

(3.54-7.59)

     

5-10

24

9.73

2.47

(1.58-3.67)

     

≥10

12

20.85

0.58

(0.30-1.01)

Breast (174)

<50

34

29.38

1.16

(0.80, 1.62)

≤5

52

13.71

3.79

(2.83-4.97)

≥50

61

37.13

1.64

(1.26, 2.11)

≤1

12

1.40

8.56

(4.42-14.96)

     

1-5

42

12.31

3.25

(2.32-4.43)

     

5-10

21

20.05

1.05

(0.65-1.60)

     

≥10

22

32.75

0.67

(0.42-1.02)

Ovary (183)

<50

23

3.68

6.25

(3.96, 9.38)

≤5

37

1.84

20.12

(14.16-27.73)

≥50

17

5.97

2.85

(1.66, 4.56)

≤1

30

0.20

152.87

(103.12-218.25)

     

1-5

7

1.64

4.26

(1.71-8.78)

     

5-10

1

2.78

0.36

(0.00-2.00)

     

≥10

2

5.03

0.40

(0.04-1.44)

Vagina (184)

<50

6

0.38

15.68

(5.73, 34.14)

≤5

7

0.29

24.43

(9.79-50.34)

≥50

10

1.38

7.22

(3.46, 13.29)

≤1

6

0.04

172.12

(62.85-374.65)

     

1-5

1

0.25

3.97

(0.05-22.11)

     

5-10

3

0.46

6.58

(1.32-19.23)

     

≥10

6

1.02

5.86

(2.14-12.75)

Bladder (188)

<50

5

1.07

4.69

(1.51, 10.95)

≤5

7

1.22

5.74

(2.30-11.82)

≥50

13

6.72

1.93

(1.03, 3.31)

≤1

3

0.15

19.69

(3.96-57.52)

     

1-5

4

1.07

3.75

(1.01-9.59)

     

5-10

4

1.99

2.01

(0.54-5.14)

     

≥10

7

4.58

1.53

(0.61-3.15)

Kidney (189)

<50

4

1.68

2.38

(0.64, 6.10)

≤5

7

1.82

3.86

(1.54-7.95)

≥50

21

9.47

2.22

(1.37, 3.39)

≤1

6

0.22

27.70

(10.12-60.30)

     

1-5

1

1.60

330.63

(0.01-3.48)

     

5-10

9

2.93

3.07

(1.40-5.82)

     

≥10

9

6.40

1.41

(0.64-2.67)

Total

<50

128

52.37

2.44

(2.04, 2.91)

≤5

210

34.33

6.12

(5.32,7.00)

≥50

269

135.77

1.98

(1.75, 2.23)

≤1

76

3.84

19.80

(15.60-24.75)

      

1-5

134

30.50

4.39

(3.68-5.21)

      

5-10

94

52.37

1.79

(1.45, 2.20)

      

≥10

93

101.45

0.92

(0.74, 1.12

  1. Bold indicates statistical significance
  2. SIR standardized incidence ratio, SPM second primary malignancy, O observed numbers of SPMs, E expected numbers of SPMs, CI confidence interval
  3. aAge at diagnosis of uterine cancer
  4. bFollow-up interval after the diagnosis of uterine cancer